NCT02129062 2017-01-16Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic LeukemiaNational Cancer Institute (NCI)Phase 2 Terminated3 enrolled 4 charts
NCT02109224 2015-08-20Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV InfectionNational Cancer Institute (NCI)Phase 1 Terminated72 enrolled